Goldman Sachs analyst Jamie Perse initiated coverage of Privia Health with a Buy rating and $32 price target. Privia is a value based care enablement company that has a "compelling" value proposition to physicians, the analyst tells investors in a research note. The analyst sees "durability" of sales growth in the mid- to high teens and EBITDA growth approximating 30% through 2026, or a "compelling financial profile."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRVA:
- Privia Health to Report Fourth Quarter 2022 Results on Tuesday, February 28
- Piper Sandler healthcare tech analysts to hold analyst/industry conference call
- Privia Health announces launches of ACOs in Delaware and North Carolina
- Privia Health Launches Two New Accountable Care Organizations
- Privia Health Enters Delaware with Beebe Healthcare; Launches Ninth ACO